227 related articles for article (PubMed ID: 31041694)
1. Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.
Fang L; Kang X; Wang Z; Wang S; Wang J; Zhou Y; Chen C; Sun X; Yan Y; Kermode AG; Peng L; Qiu W
Neurosci Bull; 2019 Oct; 35(5):853-866. PubMed ID: 31041694
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
3. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.
Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS
Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
Saadoun S; Waters P; Owens GP; Bennett JL; Vincent A; Papadopoulos MC
Acta Neuropathol Commun; 2014 Mar; 2():35. PubMed ID: 24685353
[TBL] [Abstract][Full Text] [Related]
5. More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies.
Lerch M; Schanda K; Lafon E; Würzner R; Mariotto S; Dinoto A; Wendel EM; Lechner C; Hegen H; Rostásy K; Berger T; Wilflingseder D; Höftberger R; Reindl M
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36414427
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
7. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
[TBL] [Abstract][Full Text] [Related]
8. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
[TBL] [Abstract][Full Text] [Related]
9. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
11. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
12. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
[TBL] [Abstract][Full Text] [Related]
13. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.
Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P
Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809
[TBL] [Abstract][Full Text] [Related]
14. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
[TBL] [Abstract][Full Text] [Related]
15. Extensive loss of connexins in Baló's disease: evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction.
Masaki K; Suzuki SO; Matsushita T; Yonekawa T; Matsuoka T; Isobe N; Motomura K; Wu XM; Tabira T; Iwaki T; Kira J
Acta Neuropathol; 2012 Jun; 123(6):887-900. PubMed ID: 22438105
[TBL] [Abstract][Full Text] [Related]
16. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.
Liu Y; Given KS; Harlow DE; Matschulat AM; Macklin WB; Bennett JL; Owens GP
Acta Neuropathol Commun; 2017 Mar; 5(1):25. PubMed ID: 28340598
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
[TBL] [Abstract][Full Text] [Related]
18. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
19. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.
Hamid SHM; Whittam D; Saviour M; Alorainy A; Mutch K; Linaker S; Solomon T; Bhojak M; Woodhall M; Waters P; Appleton R; Duddy M; Jacob A
JAMA Neurol; 2018 Jan; 75(1):65-71. PubMed ID: 29131884
[TBL] [Abstract][Full Text] [Related]
20. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
Akaishi T; Takahashi T; Misu T; Kaneko K; Takai Y; Nishiyama S; Ogawa R; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakashima I
Neurology; 2021 Jul; 97(1):e1-e12. PubMed ID: 33980704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
